- Poster presentation
- Open Access
Clinical characteristics, management and outcomes in patients with juvenile dermatomyositis requiring admission in pediatric intensive care unit
© Besancon et al; licensee BioMed Central Ltd. 2014
- Published: 17 September 2014
- Intensive Care Unit
- Pediatric Intensive Care Unit
- Pediatric Rheumatology
- Anaphylactic Shock
- Thrombotic Microangiopathy
Juvenile dermatomyositis (JDM) are potentially life-threatening.
We report 11 cases of severe JDM admitted in intensive care unit (ICU) to determine their early severity signs and outcomes.
We performed a retrospective study of cases of JDM admitted in ICU in 2 pediatric rheumatology centers (Paris, Toulouse) from 2005 to 2013, and compared them to the JDM patients who did not require ICU.
11/116 DMJ (9.3%) (8 girls and 3 boys, median age at diagnosis : 9.0± 3.1 years) were admitted in ICU for digestive involvement (2 with digestive perforation after pulse corticosteroids) (4 patients), bradycardia (1 patient), cardiac arrest (1 patient), hypoxemic pneumonia (1 patient), PRES syndrome due to cyclosporine (1 patient), thrombotic microangiopathy (TMA) (2 patients) and anaphylactic shock due to Rituximab (1 patient). The incidence of some clinical and biological manifestations differed from severe patients to patients with mild JDM: hyponatremia (9), hypoalbuminemia (9), generalized edema (6), anemia (hemoglobin value <8 g/dL) (8), abdominal pain (7), thrombocytopenia (platelet count : 100-150 x 109/L )(7). The patients were treated by corticosteroids (11, comprising 5 with pulse), intravenous immunoglobulins (7), plasmapheresis (7), Rituximab (4) and cyclophosphamide (2). One patient died in ICU from pneumocystosis ; 5 are currently in complete remission and 5 in partial remission with a mean follow-up duration of 4,7 years.
Generalized edema, digestive involvement (including abdominal pain), thrombocytopenia (with TMA), hyponatremia and hypoalbuminemia seem to be early warning signs of severe DMJ and should be identify to improve prognosis. Our study suggests that severe DMJ should early benefit from plasmapheresis ± Rituximab, whereas pulse corticosteroids might contribute to digestive perforation in patients presenting with digestive involvement.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.